Business
Alpha Tau Announces First Quarter 2026 Financial Results and Provides Corporate Update
- Groundbreaking interim results from U.S. REGAIN trial in recurrent glioblastoma demonstrate 100% local disease control, 67% complete response rate, and favorable safety profile - - Completion of patient enrollment in the U.S. pivotal ReSTART trial in recurrent cutaneous squamous cell carcinoma, the Company’s first U.S. pivotal study - - Pooled data from two pancreatic cancer trials presented at Digestive Disease Week (DDW) 2026 demonstrated 100% local disease control and favorable safety, the
About this update from Alpha Tau Medical Ltd.
[{"type":"image","alt":"Alpha Tau Medical Ltd.","displaySize":"","headline":null,"caption":"Alpha Tau Medical Ltd.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":215,"url":"https://media.zenfs.com/en/globenewswire.com/05605e0853ddac4177652b0fbd0afb40"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/7VgHu6alli3.BtV2lI3Eng--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTMwMQ--/https://media.zenfs.com/en/globenewswire.com/05605e0853ddac4177652b0fbd0afb40","width":300,"height":215},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/7VgHu6alli3.BtV2lI3Eng--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTMwMQ--/https://media.zenfs.com/en/globenewswire.com/05605e0853ddac4177652b0fbd0afb40","width":300,"height":215}},"lazy":false},{"type":"text","content":"- Groundbreaking interim results from U.S. REGAIN trial in recurrent glioblastoma demonstrate 100% local disease control, 67% complete response rate, and favorable safety profile -","length":180,"tagName":"p"},{"type":"text","content":"- Completion of patient enrollment in the U.S. pivotal ReSTART trial in recurrent cutaneous squamous cell carcinoma, the Company’s first U.S. pivotal study -","length":157,"tagName":"p"},{"type":"text","content":"- Pooled data from two pancreatic cancer trials presented at Digestive Disease Week (DDW) 2026 demonstrated 100% local disease control and favorable safety, the first oral presentation of Alpha DaRT® pancreatic data at a premier international gastroenterology conference -","length":277,"tagName":"p"},{"type":"text","content":"- Abstracts accepted for presentation at the 2026 ASCO Annual Meeting and at the AHNS 12th International Conference on Head and Neck Cancer, reflecting growing scientific recognition across multiple solid tumor indications -","length":224,"tagName":"p"},{"type":"text","content":"- FDA approval of an IDE supplement to expand the IMPACT pancreatic cancer trial to patients receiving gemcitabine with Abraxane® (nab-paclitaxel) and recruit additional patients -","length":185,"tagName":"p"},{"type":"text","content":"- First patient successfully treated for pancreatic cancer in Europe at CHU Grenoble Alpes under the multicenter ACAPELLA trial in France, and first patient successfully treated in Italy at the University of Verona’s Pancreas Institute -","length":237,"tagName":"p"},{"type":"text","content":"- Cash, cash equivale...